In the United States as a whole, breast cancer mortality rates have turned down to some extent in current years. That this is a recent trend is obvious from the fact that as long as the twenty years from 1970-1990, death rates demonstrated a small but considerable growth for white women of roughly 0.3 percent per year and a more considerable upsurge of 1.6 percent for black women.
In the United States, current view comes out to lend more weight to mammography screening and earlier diagnosis as the main cause for declining mortality rates, while in the UK and in Europe, where mortality rates have been declining more lately, the main present theories seem to good turn the wide usage of adjuvant tamoxifen as the cause. Because tamoxifen lowers mortality by nearly a third in long term studies of women with ER-positive breast cancers (approximately 75 percent of those diagnosed) this is surely a reasonable account.
Regular screening of women between the ages of 40 and 59 can considerably decrease breast cancer mortality in India, consistent with a study in the September 9 online issue of the Journal of the National Cancer Institute.
Breast cancer screening programs are habitually employed in developed countries where the occurrence of breast cancer is highest, and a wide health care system is prepared. The value and practicality of such screening programs in the developing world is less obvious. Even though the developing world has a lower breast cancer incidence rate, women be inclined to have more advanced disease at diagnosis and a greater risk of dying from their disease.
An important benefit of a screening program might be to recover the in general quality of care, as said by the editorialist, “but whether screening is the best method of reaching these significant purposes requires additional exploration.”
Early breast health education might be the important to lowering breast cancer mortality rates in Washington, D.C., which has the highest rates in the country, in accordance with research presented at the American Association for Cancer Research’s Seventh Annual International Conference on Frontiers in Cancer Prevention Research.
A new study proves that current declines in breast cancer mortality rates have been most considerable amongst women with estrogen receptor (ER)-positive tumors and women younger than 70.